Dapagliflozin for patients with heart failure and reduced ejection fraction

被引：3

作者：

Ferry, Abigail ^{[1
]}

机构：

[1] Allegheny Gen Hosp, Div Adv Heart Failure & Cardiac Transplant, Pittsburgh, PA 15212 USA

来源：

JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS | 2022年 / 35卷 / 09期

关键词：

dapagliflozin; heart failure; SGLT2; reduced ejection fraction; type; 2; diabetes; cardiovascular;

D O I：

10.1097/01.JAA.0000840504.15807.70

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The CDC estimates that national costs related to heart failure exceed $30 billion annually. Clinicians and researchers continue to aggressively pursue measures aimed at reducing morbidity and mortality among the 6.5 million adults affected by the disease. Dapagliflozin recently emerged as a promising FDA-approved therapy for patients with systolic heart failure, more commonly referred to as heart failure with reduced ejection fraction.

引用

页码：51 / 53

页数：3

共 8 条

[1] LONGITUDINAL CHANGES IN MEDICATION DOSING AMONG PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION: FROM THE CHAMP-HF REGISTRY [J].

Greene, Stephen ;

Fonarow, Gregg ;

DeVore, Adam ;

Sharma, Puza ;

Vaduganathan, Muthiah ;

Albert, Nancy ;

Duffy, Carol ;

Hill, C. Larry ;

McCague, Kevin ;

Patterson, J. Herbert ;

Spertus, John A. ;

Thomas, Laine ;

Williams, Fredonia ;

Hernandez, Adrian ;

Butler, Javed .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) :707-707

[2] Class effects of SGLT2 inhibitors on cardiorenal outcomes [J].

Kluger, Aaron Y. ;

Tecson, Kristen M. ;

Lee, Andy Y. ;

Lerma, Edgar V. ;

Rangaswami, Janani ;

Lepor, Norman E. ;

Cobble, Michael E. ;

McCullough, Peter A. .

CARDIOVASCULAR DIABETOLOGY, 2019, 18 (01)

[3] Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction [J].

McMurray, J. J. V. ;

Solomon, S. D. ;

Inzucchi, S. E. ;

Kober, L. ;

Kosiborod, M. N. ;

Martinez, F. A. ;

Ponikowski, P. ;

Sabatine, M. S. ;

Anand, I. S. ;

Belohlavek, J. ;

Bohm, M. ;

Chiang, C. -E. ;

Chopra, V. K. ;

de Boer, R. A. ;

Desai, A. S. ;

Diez, M. ;

Drozdz, J. ;

Dukat, A. ;

Ge, J. ;

Howlett, J. G. ;

Katova, T. ;

Kitakaze, M. ;

Ljungman, C. E. A. ;

Merkely, B. ;

Nicolau, J. C. ;

O'Meara, E. ;

Petrie, M. C. ;

Vinh, P. N. ;

Schou, M. ;

Tereshchenko, S. ;

Verma, S. ;

Held, C. ;

DeMets, D. L. ;

Docherty, K. F. ;

Jhund, P. S. ;

Bengtsson, O. ;

Sjostrand, M. ;

Langkilde, A. -M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) :1995-2008

[4] Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure [J].

Packer, Milton ;

Anker, Stefan D. ;

Butler, Javed ;

Filippatos, Gerasimos ;

Pocock, Stuart J. ;

Carson, Peter ;

Januzzi, James ;

Verma, Subodh ;

Tsutsui, Hiroyuki ;

Brueckmann, Martina ;

Jamal, Waheed ;

Kimura, Karen ;

Schnee, Janet ;

Zeller, Cordula ;

Cotton, Daniel ;

Bocchi, Edimar ;

Boehm, Michael ;

Choi, Dong-Ju ;

Chopra, Vijay ;

Chuquiure, Eduardo ;

Giannetti, Nadia ;

Janssens, Stefan ;

Zhang, Jian ;

Juanatey, Jose R. Gonzalez ;

Kaul, Sanjay ;

Brunner-La Rocca, Hans-Peter ;

Merkely, Bela ;

Nicholls, Stephen J. ;

Perrone, Sergio ;

Pina, Ileana ;

Ponikowski, Piotr ;

Sattar, Naveed ;

Senni, Michele ;

Seronde, Marie-France ;

Spinar, Jindrich ;

Squire, Iain ;

Taddei, Stefano ;

Wanner, Christoph ;

Zannad, Faiez .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (15) :1413-1424

[5] Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD [J].

Schneider, Markus P. ;

Raff, Ulrike ;

Kopp, Christoph ;

Scheppach, Johannes B. ;

Toncar, Sebastian ;

Wanner, Christoph ;

Schlieper, Georg ;

Saritas, Turgay ;

Floege, Juergen ;

Schmid, Matthias ;

Birukov, Anna ;

Dahlmann, Anke ;

Linz, Peter ;

Janka, Rolf ;

Uder, Michael ;

Schmieder, Roland E. ;

Titze, Jens M. ;

Eckardt, Kai-Uwe .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 28 (06) :1867-1876

[6]

US Food and Drug Administration, Approves Fibryga for Acquired Fibrinogen Deficiency, Potentially Ushering in a New Standard of Care

[7] Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors JACC State-of-the-Art Review [J].

Zelniker, Thomas A. ;

Braunwald, Eugene .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (04) :422-434

[8] SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials [J].

Zelniker, Thomas A. ;

Wiviott, Stephen D. ;

Raz, Itamar ;

Im, Kyungah ;

Goodrich, Erica L. ;

Bonaca, Marc P. ;

Mosenzon, Ofri ;

Kato, Eri T. ;

Cahn, Avivit ;

Furtado, Remo H. M. ;

Bhatt, Deepak L. ;

Leiter, Lawrence A. ;

McGuire, Darren K. ;

Wilding, John P. H. ;

Sabatine, Marc S. .

LANCET, 2019, 393 (10166) :31-39

← 1 →